Yang Ru-lai, Zhu Zhi-wei, Zhou Xue-lian, Zhao Zheng-yan
Affiliated Children's Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
J Zhejiang Univ Sci B. 2005 Dec;6(12):1206-9. doi: 10.1631/jzus.2005.B1206.
To study the clinical therapy and prognosis in children with transient congenital hypothyroidism (CH).
Fifty-seven children with CH diagnosed after neonatal screening were treated with low-dosage levothyroxine (L-T4). Follow-up evaluation included the determination of TT3, TT4 and TSH serum levels and the assessment of thyroid gland morphology, bone age, growth development and development quotients (DQ). A full check-up was performed at age 2, when the affected children first discontinued the L-T4 treatment for 1 month, and one year later. Development quotients were compared with a control group of 29 healthy peers.
The initial L-T4 dosage administered was 3.21-5.81 microg/(kg.d) with an average of (16.25+/-3.87) microg/d. Mean duration of therapy was (28.09+/-9.56) months. No significant difference was found between study group and control group in the DQ test (average score (106.58+/-14.40) vs (102.4+/-8.6), P>0.05) and 96.49% of the CH children achieved a test score above 85. Bone age, 99mTc scans and ultrasonographic findings were all normal, and evaluation of physical development was normal too, as were the serum levels of TT3, TT4 and TSH after one year of follow-up.
A L-T4 dosage of 3.21-5.81 microg/(kg.d) was found sufficient for the treatment of transient CH. The treated children showed satisfactory overall mental and physical development at age 2. So it is possible for CH children to stop taking medicine if their laboratory findings and physical development are all normal after regular treatment and 2-3 years of follow-up.
研究暂时性先天性甲状腺功能减退症(CH)患儿的临床治疗及预后。
对57例经新生儿筛查确诊的CH患儿采用低剂量左甲状腺素(L-T4)治疗。随访评估包括测定血清TT3、TT4和TSH水平,以及评估甲状腺形态、骨龄、生长发育和发育商(DQ)。在患儿2岁时进行全面检查,此时首次停用L-T4治疗1个月,并在1年后再次检查。将发育商与29名健康同龄儿童的对照组进行比较。
初始给予的L-T4剂量为3.21 - 5.81μg/(kg·d),平均为(16.25±3.87)μg/d。平均治疗疗程为(28.09±9.56)个月。研究组与对照组在DQ测试中无显著差异(平均得分(106.58±14.40)对(102.4±8.6),P>0.05),96.49%的CH患儿测试得分高于85分。骨龄、99mTc扫描和超声检查结果均正常,随访1年后身体发育评估正常,血清TT3、TT4和TSH水平也正常。
发现3.21 - 5.81μg/(kg·d)的L-T4剂量足以治疗暂时性CH。接受治疗的患儿在2岁时总体智力和身体发育令人满意。因此,如果CH患儿经过正规治疗和2 - 3年随访后实验室检查结果和身体发育均正常,则有可能停药。